Whole-exome sequencing and genome-wide methylation analyses identify novel disease associated mutations and methylation patterns in idiopathic hypereosinophilic syndrome

Oncotarget

Volumn 6, Issue 38, 2015, Pages 40588-40597

  Andersen, Christen Lykkegaard ^a,b   Nielsen, Helene Myrtue ^a   Kristensen, Lasse Sommer ^a   Søgaard, Alexandra ^a   Vikeså, Jonas ^a   Jønson, Lars ^a   Nielsen, Finn Cilius ^a   Hasselbalch, Hans ^b   Bjerrum, Ole Weis ^a   Punj, Vasu ^c   Grønbæk, Kirsten ^a  

^a Rigshospitalet   (Denmark)

^b ROSKILDE HOSPITAL   (Denmark)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Diagnosis; Eosinophilia; Genome wide DNA methylation analysis; Idiopathic hypereosinophilic syndrome; Next generation sequencing

Indexed keywords

BUSULFAN; CADHERIN; FIBROBLAST GROWTH FACTOR RECEPTOR; HYDROXYUREA; MYCOPHENOLATE MOFETIL; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PREDNISOLONE; BIOLOGICAL MARKER; MESSENGER RNA;

ADULT; AGED; ARTICLE; CDH17 GENE; CELL CLONE; CELL DEATH; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; EOSINOPHIL; EOSINOPHILIA; EXOME; FEMALE; FGFR GENE; GENE; GENE IDENTIFICATION; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; HEMATOLOGIC DISEASE; HUMAN; HUMAN CELL; HUMAN GENOME; HYPEREOSINOPHILIC SYNDROME; IDIOPATHIC DISEASE; IDIOPATHIC HYPEREOSINOPHILIC SYNDROME; MALE; MALIGNANT NEOPLASTIC DISEASE; MIDDLE AGED; MISSENSE MUTATION; MOLECULAR GENETICS; NEXT GENERATION SEQUENCING; ONCOGENE; PDGFRA GENE; PDGFRB GENE; POINT MUTATION; PUF60 GENE; SOMATIC MUTATION; SPLICEOSOME; T LYMPHOCYTE; TUMOR SUPPRESSOR GENE; VERY ELDERLY; CELL DIFFERENTIATION; GENETICS; GENOME-WIDE ASSOCIATION STUDY; HIGH THROUGHPUT SEQUENCING; METABOLISM; MUTATION; PATHOLOGY; PROCEDURES; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

BIOMARKERS; CELL DIFFERENTIATION; DNA METHYLATION; EXOME; FEMALE; GENOME, HUMAN; GENOME-WIDE ASSOCIATION STUDY; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; HYPEREOSINOPHILIC SYNDROME; MALE; MUTATION; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 84951015788     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.5845     Document Type: Article

References (32)

1. Brito-Babapulle F. The eosinophilias, including the idiopathic hypereosinophilic syndrome. British journal of haematology. 2003; 121:203-223.
2. Tefferi A, Patnaik MM, Pardanani A. Eosinophilia: secondary, clonal and idiopathic. British journal of haematology. 2006; 133:468-492.
3. Gotlib J. World Health Organization-defined eosinophilic disorders: 2012 update on diagnosis, risk stratification, and management. American journal of hematology. 2012; 87:903-914.
4. Valent P, Gleich GJ, Reiter A, Roufosse F, Weller PF, Hellmann A, Metzgeroth G, Leiferman KM, Arock M, Sotlar K, Butterfield JH, Cerny-Reiterer S, Mayerhofer M, Vandenberghe P, Haferlach T, Bochner BS, et al. Pathogenesis and classification of eosinophil disorders: a review of recent developments in the field. Expert review of hematology. 2012; 5:157-176.
5. Anderson RE, Hardy WR. Hypereosinophilia. Annals of internal medicine. 1968; 69:1331-1332.
6. Chusid MJ, Dale DC, West BC, Wolff SM. The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine. 1975; 54:1-27.
7. Bain BJ. Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB or FGFR1. Haematologica. 2010; 95:696-698.
8. Weller PF, Bubley GJ. The idiopathic hypereosinophilic syndrome. Blood. 1994; 83:2759-2779.
9. Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD, Them NC, Berg T, Gisslinger B, Pietra D, Chen D, Vladimer GI, Bagienski K, Milanesi C, Casetti IC, Sant'Antonio E, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. The New England journal of medicine. 2013; 369:2379-2390.
10. Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC, Avezov E, Li J, Kollmann K, Kent DG, Aziz A, Godfrey AL, Hinton J, Martincorena I, Van Loo P, Jones AV, et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. The New England journal of medicine. 2013; 369:2391-2405.
11. Perez C, Pascual M, Martin-Subero JI, Bellosillo B, Segura V, Delabesse E, Alvarez S, Larrayoz MJ, Rifon J, Cigudosa JC, Besses C, Calasanz MJ, Cross NC, Prosper F, Agirre X. Aberrant DNA methylation profile of chronic and transformed classic Philadelphia-negative myeloproliferative neoplasms. Haematologica. 2013; 98:1414-1420.
12. Christopeit M, Bartholdy B. Epigenetic signatures as prognostic tools in acute myeloid leukemia and myelodysplastic syndromes. Epigenomics. 2014; 6:371-374.
13. Munthe-Fog L, Hummelshoj T, Honore C, Madsen HO, Permin H, Garred P. Immunodeficiency associated with FCN3 mutation and ficolin-3 deficiency. The New England journal of medicine. 2009; 360:2637-2644.
14. Asmar F, Punj V, Christensen J, Pedersen MT, Pedersen A, Nielsen AB, Hother C, Ralfkiaer U, Brown P, Ralfkiaer E, Helin K, Gronbaek K. Genome-wide profiling identifies a DNA methylation signature that associates with TET2 mutations in diffuse large B-cell lymphoma. Haematologica. 2013; 98:1912-1920.
15. Kim K, Punj V, Choi J, Heo K, Kim JM, Laird PW, An W. Gene dysregulation by histone variant H2A.Z in bladder cancer. Epigenetics & chromatin. 2013; 6:34.
16. Tost J, Gut IG. DNA methylation analysis by pyrosequencing. Nature protocols. 2007; 2:2265-2275.
17. Page-McCaw PS, Amonlirdviman K, Sharp PA. PUF60: a novel U2AF65-related splicing activity. RNA. 1999; 5:1548-1560.
18. Liu J, Kouzine F, Nie Z, Chung HJ, Elisha-Feil Z, Weber A, Zhao K, Levens D. The FUSE/FBP/FIR/TFIIH system is a molecular machine programming a pulse of c-myc expression. EMBO J. 2006; 25:2119-2130.
19. Cheng L, Wang P, Yang S, Yang Y, Zhang Q, Zhang W, Xiao H, Gao H, Zhang Q. Identification of genes with a correlation between copy number and expression in gastric cancer. BMC Med Genomics. 2012; 5:14.
20. Hastings ML, Allemand E, Duelli DM, Myers MP, Krainer AR. Control of pre-mRNA splicing by the general splicing factors PUF60 and UAF(65). PloS one. 2007; 2:e538.
21. Ramakrishna M, Williams LH, Boyle SE, Bearfoot JL, Sridhar A, Speed TP, Gorringe KL, Campbell IG. Identification of candidate growth promoting genes in ovarian cancer through integrated copy number and expression analysis. PloS one. 2010; 5:e9983.
22. Liu LX, Lee NP, Chan VW, Xue W, Zender L, Zhang C, Mao M, Dai H, Wang XL, Xu MZ, Lee TK, Ng IO, Chen Y, Kung HF, Lowe SW, Poon RT, et al. Targeting cadherin-17 inactivates Wnt signaling and inhibits tumor growth in liver carcinoma. Hepatology. 2009; 50:1453-1463.
23. Li JL, Mazar J, Zhong C, Faulkner GJ, Govindarajan SS, Zhang Z, Dinger ME, Meredith G, Adams C, Zhang S, Mattick JS, Ray A, Perera RJ. Genome-wide methylated CpG island profiles of melanoma cells reveal a melanoma coregulation network. Scientific reports. 2013; 3:2962.
24. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia. 2008; 22:14-22.
25. Maciejewski JP, Padgett RA. Defects in spliceosomal machinery: a new pathway of leukaemogenesis. British journal of haematology. 2012; 158:165-173.
26. Scott LM, Rebel VI. Acquired mutations that affect premRNA splicing in hematologic malignancies and solid tumors. Journal of the National Cancer Institute. 2013; 105:1540-1549.
27. Gumireddy K, Li A, Yan J, Setoyama T, Johannes GJ, Orom UA, Tchou J, Liu Q, Zhang L, Speicher DW, Calin GA, Huang Q. Identification of a long non-coding RNA-associated RNP complex regulating metastasis at the translational step. The EMBO journal. 2013; 32:2672-2684.
28. Stijnen P, Tuand K, Varga TV, Franks PW, Aertgeerts B, Creemers JW. The Association of Common Variants in PCSK1 With Obesity: A HuGE Review and Meta-Analysis. American journal of epidemiology. 2014;180:1051-1065.
29. Romanelli V, Nakabayashi K, Vizoso M, Moran S, Iglesias-Platas I, Sugahara N, Simon C, Hata K, Esteller M, Court F, Monk D. Variable maternal methylation overlapping the nc886/vtRNA2-1 locus is locked between hypermethylated repeats and is frequently altered in cancer. Epigenetics. 2014; 9:783-790.
30. Treppendahl MB, Qiu X, Sogaard A, Yang X, Nandrup-Bus C, Hother C, Andersen MK, Kjeldsen L, Mollgard L, Hellstrom-Lindberg E, Jendholm J, Porse BT, Jones PA, Liang G, Gronbaek K. Allelic methylation levels of the noncoding VTRNA2-1 located on chromosome 5q31.1 predict outcome in AML. Blood. 2012; 119:206-216.
31. Gerdes H, Chen Q, Elahi AH, Sircar A, Goldberg E, Winawer D, Urmacher C, Winawer SJ, Jhanwar SC. Recurrent deletions involving chromosomes 1, 5, 17, and 18 in colorectal carcinoma: possible role in biological and clinical behavior of tumors. Anticancer Res. 1995; 15:13-24.
32. Mohan SK, Yu C. The IL1alpha-S100A13 heterotetrameric complex structure: a component in the non-classical pathway for interleukin 1alpha secretion. The Journal of biological chemistry. 2011; 286:14608-14617.